Changes in urinary metabolic profiles of colorectal cancer patients enrolled in a prospective cohort study (ColoCare)

Metabolomics

Volumn 11, Issue 4, 2015, Pages 998-1012

  Liesenfeld, David B ^a,c   Habermann, Nina ^a,c   Toth, Reka ^a,c   Owen, Robert W ^a,c   Frei, Eva ^a,c   Böhm, Jürgen ^a,c   Schrotz King, Petra ^a,c   Klika, Karel D ^a   Ulrich, Cornelia M ^a,b,c,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

^c German Consortium for Translational Cancer Research (DKTK)   (Germany)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Biomarkers; Cohort; Colorectal cancer; Gas chromatography mass spectrometry (GC MS); Metabolomics; Nuclear magnetic resonance (NMR)

Indexed keywords

1 METHYLNICOTINAMIDE; 2 HYDROXYGLUTARIC ACID; 2, 3 BUTANEDIOL; ACONITIC ACID; ARABINITOL; BIOLOGICAL MARKER; BUTYRIC ACID; CARNITINE; CYSTINE; DOPAMINE; GLUCURONIDE; GLUTAMIC ACID; GLUTAMINE; GLYCEROL; GUAIACOL; HIPPURIC ACID; HISTIDINE; HYDROQUINONE; HYPOXANTHINE; INDICAN; INOSITOL; N ACETYLGLUCOSAMINE; PARA CRESOL; PYROGALLOL; PYROGLUTAMIC ACID; SUGAR ACID; TARTARIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; XYLOSE;

ADULT; ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; ENZYME SPECIFICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLOME; METABOLOMICS; MICROBIOME; MIDDLE AGED; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; URINALYSIS;

BACTERIA (MICROORGANISMS);

EID: 84931564158     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-014-0758-3     Document Type: Article

References (58)

1. Aa, J., et al. (2012). Metabolic features of the tumor microenvironment of gastric cancer and the link to the systemic macroenvironment. Metabolomics,8, 164–173.
2. ACS. (2013). Cancer facts & figures 2013. Atlanta: ACS.
3. Barupal, D. K., et al. (2012). MetaMapp: Mapping and visualizing metabolomic data by integrating information from biochemical pathways and chemical and mass spectral similarity. BMC Bioinformatics,13, 99.
4. Bates, D., Maechler, M., Bolker, B., & Walker, S. (2013). lme4: Linear mixed-effects models using Eigen and S4. http://CRAN.R-project.org/package=lme4. Accessed 15 Oct 2014.
5. Beck, S. A., & Tisdale, M. J. (1989). Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Research,49, 3800–3804.
6. Bellomi, M., et al. (2005). Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma. European Radiology,15, 2469–2474.
7. Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological),57, 289–300.
8. Biondi, A., et al. (2013). Laparoscopic vs. open approach for colorectal cancer: Evolution over time of minimal invasive surgery. BMC surgery,13, 1471–2482.
9. Bone, E., Tamm, A., & Hill, M. (1976). The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. American Journal of Clinical Nutrition,29, 1448–1454.
10. Boutwell, R. K., & Bosch, D. K. (1959). The tumor-promoting action of phenol and related compounds for mouse skin. Cancer Research,19, 413–424.
11. Carman, R. J., Van Tassell, R. L., Kingston, D. G., Bashir, M., & Wilkins, T. D. (1988). Conversion of IQ, a dietary pyrolysis carcinogen to a direct-acting mutagen by normal intestinal bacteria of humans. Mutation Research,206, 335–342.
12. Chan, E. C., et al. (2009). Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). Journal of Proteome Research,8, 352–361.
13. Cheng, Y., et al. (2012). Distinct urinary metabolic profile of human colorectal cancer. Journal of Proteome Research,11, 1354–1363.
14. Chowdhury, R., Yeoh, K. K., Tian, Y. M., Hillringhaus, L., Bagg, E. A., Rose, N. R.,et al. (2011). The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Reports, 12(5), 463–469. doi:10.1038/embor.2011.43
15. Denkert, C., et al. (2008). Metabolite profiling of human colon carcinoma: Deregulation of TCA cycle and amino acid turnover. Molecular Cancer,7, 72.
16. Deryugina, E. I., & Quigley, J. P. (2006). Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews,25, 9–34.
17. Dunn, W. B., et al. (2011). Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols,6, 1060–1083.
18. Farshidfar, F., et al. (2012). Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Medicine,4, 2–13.
19. Ferlay, J., et al. (2013). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer,49, 1374–1403.
20. Heavey, P. M., & Rowland, I. R. (2004). Microbial–gut interactions in health and disease. Gastrointestinal cancer. Best Practice & Research Clinical Gastroenterology,18, 323–336.
21. Højsgaard, U. H. S. (2013). pbkrtest: Parametric bootstrap and Kenward Roger based methods for mixed model comparison. http://CRAN.R-project.org/package=pbkrtest. Accessed 15 Oct 2014.
22. Kanani, H., Chrysanthopoulos, P. K., & Klapa, M. I. (2008). Standardizing GC–MS metabolomics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences,871, 191–201.
23. Kern, K. A., & Norton, J. A. (1988). Cancer cachexia. JPEN Journal of Parenteral and Enteral Nutrition,12, 286–298.
24. Kind, T., Tolstikov, V., Fiehn, O., & Weiss, R. H. (2007). A comprehensive urinary metabolomic approach for identifying kidney cancer. Analytical Biochemistry,363, 185–195.
25. Kondo, Y., et al. (2011). Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomarkers in Medicine,5, 451–460.
26. Leichtle, A. B., et al. (2012). Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics,8, 643–653.
27. Liesenfeld, D. B., Habermann, N., Owen, R. W., Scalbert, A., & Ulrich, C. M. (2013). Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol Biomarkers Prevention,22, 2182–2201.
28. Losman, J. A., & Kaelin, W. G., Jr. (2013). What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Development,27, 836–852.
29. Ma, Y. L., et al. (2009). Ultra-high performance liquid chromatography–mass spectrometry for the metabolomic analysis of urine in colorectal cancer. Digestive Diseases and Sciences,54, 2655–2662.
30. Maeda, J., et al. (2010). Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer,10, 690–698.
31. Mal, M., Koh, P. K., Cheah, P. Y., & Chan, E. C. Y. (2009). Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Communications in Mass Spectrometry,23, 487–494.
32. Mal, M., Koh, P. K., Cheah, P. Y., & Chan, E. C. Y. (2012). Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Analytical and Bioanalytical Chemistry,403, 483–493.
33. Marchesi, J. R., et al. (2011). Towards the Human Colorectal Cancer Microbiome. PLoS One,6, e20447.
34. Miyagi, Y., et al. (2011). Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One,6, e24143.
35. Moffett, J. R., & Namboodiri, M. A. (2003). Tryptophan and the immune response. Immunology and Cell Biology,81, 247–265.
36. Nambiar, P. R., Gupta, R. R., & Misra, V. (2010). An “Omics” based survey of human colon cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis,693, 3–18.
37. Nishiumi, S., et al. (2012). A novel serum metabolomics-based diagnostic approach for colorectal cancer. Plos One,7, e40459.
38. Normanno, N., et al. (2013). Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. Journal of Cellular Biochemistry,114, 514–524.
39. Opitz, C. A., et al. (2011). An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature,478, 197–203.
40. Owen, R. W., Spiegelhalder, B., & Bartsch, H. (2000). Generation of reactive oxygen species by the faecal matrix. Gut,46, 225–232.
41. Paxton, R., Scislowski, P. W., Davis, E. J., & Harris, R. A. (1986). Role of branched-chain 2-oxo acid dehydrogenase and pyruvate dehydrogenase in 2-oxobutyrate metabolism. Biochemical Journal,234, 295–303.
42. Perroud, B., et al. (2006). Pathway analysis of kidney cancer using proteomics and metabolic profiling. Molecular Cancer,5, 1–17.
43. Pluskal, T., Castillo, S., Villar-Briones, A., & Oresic, M. (2010). MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics,11, 395–406.
44. Pollard, P. J., et al. (2005). Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Human Molecular Genetics,14, 2231–2239.
45. Qiu, Y. P., et al. (2009). Serum metabolite profiling of human colorectal cancer using GC–TOFMS and UPLC–QTOFMS. Journal of Proteome Research,8, 4844–4850.
46. Qiu, Y. P., et al. (2010). Urinary metabonomic study on colorectal cancer. Journal of Proteome Research,9, 1627–1634.
47. Ritchie, S. A., et al. (2010). Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Medicine,8, 1–20.
48. Steele, R. D. (1982). Transaminative metabolism of alpha-amino-n-butyrate in rats. Metabolism,31, 318–325.
49. Sumner, L., et al. (2007). Proposed minimum reporting standards for chemical analysis. Metabolomics,3, 211–221.
50. Thysell, E., et al. (2010). Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One,5, e14175.
51. van den Berg, R., Hoefsloot, H., Westerhuis, J., Smilde, A., & van der Werf, M. (2006). Centering, scaling, and transformations: Improving the biological information content of metabolomics data. BMC Genomics,7, 142.
52. Wang, W. Z., et al. (2010). Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography–mass spectrometry. Molecular Biosystems,6, 1947–1955.
53. Warrack, B. M., et al. (2009). Normalization strategies for metabonomic analysis of urine samples. Journal of Chromatography B,877, 547–552.
54. Wu, H., et al. (2009). Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Analytica Chimica Acta,648, 98–104.
55. Xia, J., Broadhurst, D., Wilson, M., & Wishart, D. S. (2013). Translational biomarker discovery in clinical metabolomics: An introductory tutorial. Metabolomics,9, 280–299.
56. Xia, J., Mandal, R., Sinelnikov, I. V., Broadhurst, D., & Wishart, D. S. (2012). MetaboAnalyst 2.0—A comprehensive server for metabolomic data analysis. Nucleic Acids Research,40, 2.
57. Xiao, C., Hao, F., Qin, X., Wang, Y., & Tang, H. (2009). An optimized buffer system for NMR-based urinary metabonomics with effective pH control, chemical shift consistency and dilution minimization. Analyst,134, 916–925.
58. Zhang, X., et al. (2012). Metabolite profiling of plasma and urine from rats with TNBS-induced acute colitis using UPLC–ESI–QTOF–MS-based metabonomics—A pilot study. FEBS Journal,279, 2322–2338.